Navigating SaMD Registration in the US

6 min read

Software is steadily becoming a clinical actor, detecting disease earlier, prioritizing care pathways, and reducing variation in how clinicians interpret data. But in the United States, market entry is not just a technical milestone, it is a credibility milestone. The path to registration requires a straightforward Regulatory narrative, disciplined evidence, and an operating model that can sustain change without eroding safety.

For SaMD teams, the most frequent source of delay is not a single missing document, it is misalignment. Misalignment between intended use and risk classification, between engineering outputs and regulatory expectations, or between what the software actually does and what the labeling implies it does. Strong outcomes depend on establishing that alignment early and keeping it intact as the product evolves.

This article outlines a practical, future ready approach to US registration for SaMD how to translate product intent into FDA regulations for medical devices, how to navigate FDA medical device classification, and how to build a submission strategy that anticipates evidence expectations, iteration, and post market responsibilities.

Start with “device or not” and define your intended use with precision.

Before considering pathways, teams need clarity on whether the software function falls within FDA’s scope as a medical device and why. In practice, this is an intended use exercise. The FDA evaluates not only explicit claims but also implied claims, user context, and how the product is presented. Small wording decisions, especially around diagnosis, treatment, or disease-specific recommendations, can shift regulatory status and risk.

A precise intended use does two important things. First, it sets the boundaries for what you must validate. Second, it anchors downstream decisions on classification and evidence. If your claim is broader than the evidence you can reasonably generate, you create friction later. If the claim is too narrow, you may end up resubmitting when you expand functionality. The most durable approach is to write intended use in a way that is clinically meaningful, testable, and stable through foreseeable product evolution.

Understand classification as a strategic decision, not an administrative step.

US registration is heavily shaped by FDA medical device classification, because class determines regulatory controls and the likely pathway to market authorization. Many SaMD teams initially treat classification as a quick database lookup. In reality, classification requires a defensible rationale, What clinical risk exists if the software is wrong, and how directly the output drives clinical action?

The FDA’s device classification resources, including the Product Code Classification Database, are helpful in grounding this rationale, especially when you are identifying a product code, panel, and regulatory controls in the early strategy phase. You can review the FDA’s Product Code Classification Database as you refine your approach, using it to align your claims and indications with established categories and controls.

Two practical insights matter here:

If you cannot identify a reasonable predicate category, you may be heading toward De Novo rather than 510(k).
If your claims expand into higher impact decision making, your classification assumptions can shift, so classification should be treated as a living rationale, revisited when functionality or intended use changes.

Choose the right market authorization path and design evidence around it.

For many SaMD products, the most common route is a 510(k), but only when substantial equivalence to a predicate device can be established. The 510(k) concept is simple: show your device is as safe and effective as a legally marketed predicate, but in software, it becomes nuanced. “Equivalent” is not only about features but intended use, technological characteristics, and performance evidence.

The FDA’s 510(k) overview is a suitable anchor for understanding when a 510(k) is required and how the FDA frames substantial equivalence. It is helpful to reference this early while shaping 510(k) submissions for medical devices and aligning stakeholder expectations.

From a thought leadership standpoint, the critical shift is this to don’t build evidence to “fill sections.” Build evidence to defend your clinical narrative. A strong evidence package typically connects:

Analytical validation (does the software compute correctly and reliably?)
Clinical validation (does it perform meaningfully in the intended population and setting?)
Usability and human factors (can intended users interpret and act on outputs safely?)
Cybersecurity and data integrity (is the system resilient in real-world use?)

This is also where 510(k) documentation requirements become more than formatting; they become a discipline of traceability. When requirements, risk controls, verification, and validation are consistently connected, reviews become more efficient and changes are easier to govern.

Treat “registration” and “clearance/authorization” as different steps in the journey.

A common misconception is that FDA medical device registration is the same thing as FDA clearance or approval. In reality, “registration and listing” refers to establishment registration and device listing obligations, while market authorization is obtained through pathways such as 510(k), De Novo, or PMA, as applicable.

The FDA explains this clearly in its Device Registration and Listing overview, and SaMD manufacturers benefit from aligning internal teams early so they don’t compress registration tasks into the wrong timeline

Where this becomes strategic is in planning: your operational readiness (quality system maturity, complaint handling, cybersecurity patch processes) should be aligned with the step you are entering. Mature teams avoid “submission only readiness” and instead build the operational system that sustains compliance after launch.

Align with the FDA medical device approval process reality for SaMD.

Teams often use the phrase FDA medical device approval process to describe all US market authorization, but the FDA’s terminology and expectations vary by pathway. Most SaMD in moderate-risk categories are “cleared” via 510(k), some novel products are “granted” De Novo classification, and high-risk products require PMA “approval.” The strategic point is not semantics, it is lifecycle accountability. Each pathway has different expectations for evidence depth, review focus, and post-market controls.

For SaMD, two trends are shaping outcomes:

Lifecycle emphasis: regulators want confidence that your software remains safe as it changes, especially for frequent updates.
Digital health policy clarity: the FDA increasingly centralizes digital health expectations through its digital health ecosystem and guidance collections, helping teams interpret how software functions fit within FDA regulations for medical devices.

This is why strong SaMD teams invest early in consistent change impact assessment, validation planning that scales across versions, and a post-market monitoring mindset that is evidence-driven rather than reactive.

Close with a strategy that scales beyond the first submission

Successfully navigating US registration is rarely about “One big push.” It is about building a repeatable system, one that keeps intended use stable, classification rationale defensible, evidence traceable, and changes governed with discipline. When those fundamentals are in place, teams can move faster without increasing Regulatory risk.

In practice, teams that design US readiness as part of a lifecycle discipline linking classification logic, evidence durability, and change governance tend to align more consistently with expectations outlined in the Comprehensive Guide to Software as a Medical Device (SaMD) Compliance & Global Registration.

Contact Freyr Solutions to discuss your SaMD Regulatory strategy and discover how Freyr can streamline your global registrations.

FAQs: Global Market Access for SaMD

What’s the difference between FDA medical device registration and clearance/approval for SaMD?

FDA medical device registration (registration and listing) is an establishment/device listing requirement, while market authorization depends on the appropriate pathway, commonly 510(k) clearance, De Novo classification, or PMA approval. They are related but distinct steps, and the timing and documentation expectations differ.

How does FDA medical device classification affect the pathway for SaMD?

FDA medical device classification determines the level of Regulatory controls and influences which authorization route applies. For many SaMD products, classification affects whether a predicate exists for a 510(k), whether De Novo is more appropriate, and the amount of clinical or analytical evidence expected.

When do SaMD companies typically need a 510(k)?

SaMD companies typically pursue a 510(k) when they can demonstrate substantial equivalence to a legally marketed predicate with a similar intended use and comparable technological characteristics. When no appropriate predicate exists, De Novo may be the more realistic option.

What are the most important 510(k) documentation requirements for SaMD?

Key 510(k) documentation requirements typically include clear intended use, software description, risk management, verification and validation evidence, cybersecurity considerations, labeling, and performance testing that supports substantial equivalence. Strong traceability between requirements, risks, and testing is often critical for efficient review.

What should teams understand about the FDA medical device approval process for SaMD?

The term FDA medical device approval process is often used broadly, but in practice SaMD may be cleared via 510(k), granted De Novo, or approved via PMA depending on risk and novelty. Regardless of the pathway, the FDA expects disciplined lifecycle controls, especially around change management, validation across versions, and post-market monitoring.